“Good bacteria” is promising for clinical treatment of Crohn’s disease and ulcerative colitis

image: Balfour Sartor, MD to see More Credit: UNC School of Medicine Chapel Hill, NC- Nature Communications A consortium of bacteria designed to complement the disproportionate microbiome deficiency or underestimated function of patients with inflammatory bowel disease (IBD) prevented and treated chronic immune colitis in a humanized mouse model. It shows that. The lead author of this study, Dr. Balforserter, a prominent professor of midget medicine, microbiology and immunology, and co-director of the UNC Interdisciplinary IBD Center, found that the results are for the treatment of patients with Crohn's disease and ulcerative colitis He said he would encourage it to be used. "The idea for this treatment is to restore the normal functioning of protective bacteria in the gut, rather than treating the condition with traditional immunosuppressive drugs that can cause side effects such as infections and tumors, and for IBD. It's about targeting the source, "said Sartor. A viable consortium called GUT-103 and GUT-108 was developed by the biotechnology company Gusto Global. GUT-103 is composed of 17 types of bacteria, which work together to protect and nourish each other. GUT-108 is an improved version of GUT-103, using 11 human isolates associated with 17 strains. These combinations allow the bacteria to stay in the colon for extended periods of time, in contrast to other probiotics that cannot live in the intestines and pass through the system quickly. GUT-103 and GUT-108 were specially developed and orally administered to "sterile" mice (bacter-free) treated with specific human bacteria three times a week to create a humanized mouse model. .. The Therapeutic Bacterial Consortium worked by addressing upstream targets rather than targeting a single cytokine to block the downstream inflammatory response, reversing established inflammation. "It also expanded the resident protective bacteria while reducing pathogens (potentially harmful bacteria) and producing metabolites that promote mucosal healing and immunomodulatory responses," Sarter said. Stated. "Simply put, treatment has increased the number of good people and reduced the number of bad people." Due to the solid results seen in this study and the need for more alternative therapies for Crohn's disease, Sartor hopes that GUT-103 and GUT-108 will be studied in future Phase 1 and Phase 2 clinical trials. I'm out. He will continue to work with Gusto Global to further explore the use of the Bacterial Consortium.### This work was funded by Gusto Global, LLC. Dr. Daniel Van der Lelie, CEO of Gusto Global, is the first author of this study. Sterile mice were donated by grants from the National Institutes of Health (NIH) and the Crohn's and Colitis Foundation. Disclaimer: AAAS and Eurek Alert! We are not responsible for the accuracy of news releases posted to EurekAlert! To use the information by contributing to the institution or through the Eurek Alert system. .. Pictures Credit

ExBulletin

“Good bacteria” is promising for clinical treatment of Crohn’s disease and ulcerative colitis

Health

“Good bacteria” is promising for clinical treatment of Crohn’s disease and ulcerative colitis

Related

Recent Posts

Add ExBulletin to your Home screen!